A study of BOS-580 in obese subjects at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH) with an extension
Trial overview
Part A: Number of participants with treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)
Timeframe: Up to Week 16
Part A: Change from Baseline (CFB) in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Timeframe: Baseline (Pre-dose on Day 1) and at Week 12
Part A: Change from Baseline in heart rate
Timeframe: Baseline (Pre-dose on Day 1) and at Week 12
Part B: Number of participants with TEAEs and TESAEs
Timeframe: Up to Week 28
Part B: Change from Baseline in systolic blood pressure and diastolic blood pressure
Timeframe: Baseline (Pre-dose on Day 1) and at Week 24
Part B: Change from Baseline in heart rate
Timeframe: Baseline (Pre-dose on Day 1) and at Week 24
Part C: Number of participants with TEAEs and TESAEs
Timeframe: Up to 28 weeks (Study Weeks 28 to 56)
Part C: Change from Baseline in systolic blood pressure and diastolic blood pressure
Timeframe: Baseline (Pre-dose on Day 1) and at study Week 56
Part C: Change from Baseline in heart rate
Timeframe: Baseline (Pre-dose on Day 1) and at Study Week 56
Part D: Number of participants with TEAEs and TESAEs
Timeframe: Up to Week 52
Part D: Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 36
Timeframe: Baseline (Pre-dose on Day 1) and at Week 36
Part D: Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 48
Timeframe: Baseline (Pre-dose on Day 1) and at Week 48
Part D: Change from Baseline in heart rate at Week 36
Timeframe: Baseline (Pre-dose on Day 1) and at Week 36
Part D: Change from Baseline in heart rate at Week 48
Timeframe: Baseline (Pre-dose on Day 1) and Week 48
Part A: Number of participants with Grade 3 and Grade 4 hematologic abnormalities according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Timeframe: At Week 12
Part A: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities according to NCI-CTCAE
Timeframe: At Week 12
Part B: Number of participants with Grade 3 and Grade 4 hematologic abnormalities according to NCI-CTCAE
Timeframe: At Week 24
Part B: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities according to NCI-CTCAE
Timeframe: At Week 24
Part C: Number of participants with Grade 3 and Grade 4 hematologic abnormalities according to NCI-CTCAE
Timeframe: At Study Week 56
Part C: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities according to NCI-CTCAE
Timeframe: At Study Week 56
Part D: Number of participants with Grade 3 and Grade 4 hematologic abnormalities at Week 36 according to NCI-CTCAE
Timeframe: At Week 36
Part D: Number of participants with Grade 3 and Grade 4 hematologic abnormalities at Week 48 according to NCI-CTCAE
Timeframe: At Week 48
Part D: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities at Week 36 according to NCI-CTCAE
Timeframe: At Week 36
Part D: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities at Week 48 according to NCI-CTCAE
Timeframe: At Week 48
Part A: Serum concentration of Efimosfermin on Day 8
Timeframe: Pre-dose on Day 8
Part A: Observed concentration of Efimosfermin at the end of the dosing interval (Ctrough)
Timeframe: Pre-dose on Days 29, 57, 85 and 113
Part B: Serum concentration of Efimosfermin on Day 7
Timeframe: Pre-dose on Day 7
Part B: Observed concentration of Efimosfermin at the end of the dosing interval (Ctrough)
Timeframe: Pre-dose on Days 29, 57, 85, 113, 141, 169 and 197
Part B: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC [0-tau]) of Efimosfermin
Timeframe: Pre-dose on Days 29, 57, 85, 113, 141, 169 and 197
Part C: Observed concentration of Efimosfermin at the end of the dosing interval (Ctrough)
Timeframe: Pre-dose on Study Days 197, 225, 253, 281, 309, 337, 365 and 393
Part C: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC [0-tau]) of Efimosfermin
Timeframe: Pre-dose on Study Days 197, 225, 253, 281, 309, 337, 365 and 393
- Inclusion Criteria (Part A and Part B):
- Participant is either male or female and 18 to 75 years of age inclusive, at the time of signing the informed consent
- Participant is either male or female and 18 to 75 years of age inclusive, at the time of signing the informed consent
- Obese participants with body mass index (BMI) of ≥ 27 kg/m^2
- Hepatic fat fraction (HFF) measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) ≥8%
- Liver fibrosis assessment based on a vibration controlled transient elastography (VCTE) liver stiffness measurement (LSM) score of 7.0 to 9.9 kPa (Part A only) inclusive or 7.0 to 20.0 kPa (Part B only) inclusive and Liver injury assessment measured by aspartate aminotransferase (AST) >25U/L. A qualifying historical biopsy (confirmed eligibility based on the central pathology read) supersedes the LSM, controlled attenuation parameter (CAP) score criteria and AST criteria.
- Histopathologically confirmed F2 or F3 stage NASH on a diagnostic liver biopsy performed during Screening or within 6 months prior to the first day of dosing for historical biopsies (Part B only).
- History or presence of at least 2 of 4 components of metabolic syndrome: obesity/overweight, dyslipidemia (high triglycerides and/or low high density lipoprotein [HDL]), type 2 diabetes with elevated glycated hemoglobin (HbA1c), and hypertension. Inclusion Criteria (Part C):
- Participant must have completed the Part B of the study.
- Participant willing to undergo liver biopsy at Week 56
- NASH F stage
- BMI of ≥ 25 kg/m^2
- Liver fibrosis based on assessments taken during screening visit
- Participant should be willing and able to undergo liver biopsy during Screening (if a historical biopsy within 12 months prior to Screening is not available) and per protocol as judged by the Investigator.
- Other inclusion criteria may apply Exclusion Criteria (Part A and Part B):
- Documented clinical, laboratory or radiologic evidence of cirrhosis (compensated or decompensated)
- Triglycerides ≥ 500 mg/dL
- Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months from Screening, whichever is smaller)
- History of type 1 diabetes, diabetic ketoacidosis, or positive glutamic acid decarboxylase (GAD) auto-antibodies (latent autoimmune diabetes in adults)
- Hemoglobin A1c > 9.5%
- Participants with a condition that requires substantial anticoagulant medication may not be eligible for the study enrollment (e.g., deep vein thrombosis). Exclusion Criteria (Part C):
- Participants that received their 24 week dose in Part B > 10 weeks prior to enrollment into Part C Exclusion Criteria (Part D):
- Other causes of chronic liver disease
- Documented evidence or history of decompensated liver cirrhosis.
- History of type 1 diabetes or poorly controlled type 2 diabetes.
- History of malignancy.
- Use of other investigational drugs.
- Other exclusion criteria may apply
Inclusion Criteria (Part A and Part B):
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]